---
schema_version: "secwatch.filing_event.v1"
accession: "0001566044-25-000007"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:41:12.455362+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VYNE reports Q3 net loss $7.3M; cash $32.7M; strategic review ongoing

## Summary
- Net loss $7.3M ($0.17 per share) vs $12.2M ($0.29) in Q3 2024; revenue $0.2M from Finacea royalty.
- Cash, cash equivalents and marketable securities $32.7M as of Sep 30, 2025; runway into first half 2027.
- FDA partial clinical hold on VYN202 for male subjects; 12-week dog tox study ongoing to resolve.
- Phase 2b repibresib gel for vitiligo failed primary endpoint F-VASI50; trial being terminated.
- Board initiated strategic review in Aug 2025; evaluating partnerships, M&A, asset sales; LifeSci Capital engaged.

## SEC filing metadata
- accession: 0001566044-25-000007
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000156604425000007/0001566044-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000156604425000007/mnlo-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001566044-25-000007
- JSON: https://secwatch.observer/filing/0001566044-25-000007.json
- Plain text: https://secwatch.observer/filing/0001566044-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.